At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ACXP Acurx Pharmaceuticals, LLC*
Post-Mkt 08-18 18:09:55 EDT
1.44
-0.21
-12.73%
盘后1.42
-0.02-1.06%
17:53 EDT
High1.65Low1.41Vol262.20K
Open1.57D1 Closing1.65Amplitude14.85%
Mkt Cap7.59MTradable Cap6.00MTotal Shares5.27M
T/O391.20KT/O Rate6.29%Tradable Shares4.17M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Acurx Pharmaceuticals Receives FDA Conditional Acceptance and Uspto Trademark Allowance for the Company's Brand Name for Ibezapolstat
THOMSON REUTERS  ·  08-17 20:01
Acurx Pharmaceuticals Receives FDA Conditional Acceptance and Uspto Trademark Allowance for the Company's Brand Name for Ibezapolstat
Analysts Are Bullish on Top Healthcare Stocks: Candel Therapeutics (CADL), Acurx Pharmaceuticals (ACXP)
TIPRANKS  ·  08-14
Analysts Are Bullish on Top Healthcare Stocks: Candel Therapeutics (CADL), Acurx Pharmaceuticals (ACXP)
Acurx Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Reuters  ·  08-14
Acurx Pharmaceuticals Inc Reports Results for the Quarter Ended June 30 - Earnings Summary
Acurx Pharmaceuticals Q2 EPS $(0.53) Misses $(0.37) Estimate
Benzinga Earnings  ·  08-14
Acurx Pharmaceuticals Q2 EPS $(0.53) Misses $(0.37) Estimate
Acurx Pharmaceuticals Q2 EPS USD -0.53
THOMSON REUTERS  ·  08-14
Acurx Pharmaceuticals Q2 EPS USD -0.53
Press Release: Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 Results and Provides Business Update
Dow Jones  ·  08-14
Press Release: Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 Results and Provides Business Update
Acurx Net Loss Flat at $2.26 Million in Q2 2026
Reuters  ·  08-14
Acurx Net Loss Flat at $2.26 Million in Q2 2026
Calendar of U.S. Earnings Expected in the Week Ahead
Dow Jones  ·  08-13
Calendar of U.S. Earnings Expected in the Week Ahead
ACXP Advances Ibezapolstat Trial in High-Risk C. Difficile Patients
TIPRANKS  ·  08-13
ACXP Advances Ibezapolstat Trial in High-Risk C. Difficile Patients
Acurx Pharmaceuticals Inc Expected to Post a Loss of 38 Cents a Share - Earnings Preview
Reuters  ·  08-12
Acurx Pharmaceuticals Inc Expected to Post a Loss of 38 Cents a Share - Earnings Preview
Acurx Says Japan, Mexico Patent Offices Grant New Patents for DNA Polymerase IIIC Inhibitor Antibiotics
Reuters  ·  08-12
Acurx Says Japan, Mexico Patent Offices Grant New Patents for DNA Polymerase IIIC Inhibitor Antibiotics
Acurx partners with Leiden University Medical Center to develop its antibiotics
TIPRANKS  ·  08-10
Acurx partners with Leiden University Medical Center to develop its antibiotics
Acurx Partners with Leiden UMC to Develop First 3D Structure of MRSA PolC Bound to Its Antibiotic Inhibitor
Reuters  ·  08-10
Acurx Partners with Leiden UMC to Develop First 3D Structure of MRSA PolC Bound to Its Antibiotic Inhibitor
Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase Iiic Inhibitor Antibiotics
THOMSON REUTERS  ·  08-10
Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase Iiic Inhibitor Antibiotics
Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE) and Acurx Pharmaceuticals (ACXP)
TIPRANKS  ·  08-03
Analysts Offer Insights on Healthcare Companies: Wave Life Sciences (WVE) and Acurx Pharmaceuticals (ACXP)
Acurx Says FDA Open to Single Phase 3 Trial to Support Ibezapolstat CDI NDA Filing
Reuters  ·  08-03
Acurx Says FDA Open to Single Phase 3 Trial to Support Ibezapolstat CDI NDA Filing
Acurx Pharmaceuticals - Receives FDA Guidance on Single Phase 3 Trial Nda for Ibezapolstat in Cdi
THOMSON REUTERS  ·  08-03
Acurx Pharmaceuticals - Receives FDA Guidance on Single Phase 3 Trial Nda for Ibezapolstat in Cdi
FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. Difficile Infection
THOMSON REUTERS  ·  08-03
FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. Difficile Infection
Acurx Pharmaceuticals - FDA Agrees Nda Filing Possible for Both Treatment and Recurrence Reduction with Successful Trials
THOMSON REUTERS  ·  08-03
Acurx Pharmaceuticals - FDA Agrees Nda Filing Possible for Both Treatment and Recurrence Reduction with Successful Trials
Acurx Pharmaceuticals - FDA Open to Pre-Nda Discussion After Single Phase 3 Trial if Efficacy Results are Robust
THOMSON REUTERS  ·  08-03
Acurx Pharmaceuticals - FDA Open to Pre-Nda Discussion After Single Phase 3 Trial if Efficacy Results are Robust

Introduction

Company Name.
Acurx Pharmaceuticals, LLC*
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
Issue price:
--